Immune Response

Immune Response-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
NEW Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity ...
May 25, 2017 - N°20170146526

Nanoparticle-based compositions, assays, kits, methods and platforms for delivering an antigen (peptides, proteins) or a nucleic acid encoding an antigen to professional apcs (papcs) result in the generation of autologous apcs that present a natural peptide repertoire of the antigen for use in assessing the efficacy of a vaccine (e. G., a cytotoxic t lymphocyte (ctl) response to a particular ...
NEW Methods for the treatment of infections and tumors
May 25, 2017 - N°20170146520

Pd-1 antagonists are disclosed that can be used to reduce the expression or activity of pd-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these pd-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated ...
NEW Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
May 25, 2017 - N°20170145417

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, ...
NEW Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
May 25, 2017 - N°20170145082

The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of alzheimer's ...
NEW Novel peptides and combination of peptides for use in immunotherapy against various tumors
May 25, 2017 - N°20170145073

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated t-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor ...
NEW Novel peptides and combination of peptides for use in immunotherapy against various tumors
May 25, 2017 - N°20170145072

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated t-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor ...
NEW Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Novel mucosal adjuvants and delivery systems
May 25, 2017 - N°20170143823

Adjuvants comprising chitosan cross-linked with an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided. The adjuvant-antigen combinations can be used in vaccine formulations and the vaccine formulations can be used in methods to vaccinate animals against the source of the antigen or to ...
NEW Immunogenic combinations
May 25, 2017 - N°20170143820

Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit ...
NEW Dengue virus vaccine
May 25, 2017 - N°20170143817

Recombinant fusion proteins including a dengue virus eiii and an e2 subunit derived from a thermophilic bacterium are described. Also described are expression vectors including a polynucleotide that encodes the recombinant fusion protein and a promoter. Also described are vaccine compositions that include either the recombinant fusion protein, polynucleotide, or both. Also described are methods of generating an immune response ...
NEW Immunotherapy using cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
May 25, 2017 - N°20170143814

The present invention provides cell-targeting molecules which can deliver a cd8+ t-cell epitope cargo to the mhc class i presentation pathway of the cell. The cell-targeting molecules of the invention can be used to deliver virtually any cd8+ t-cell epitope from an extracellular space to the mhc class i pathway of a target cell, which may be a malignant cell ...
NEW Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
May 25, 2017 - N°20170143810

Disclosed herein are an immunogenic glycopeptide for inducing immune response to treat cancer. Other aspects of the present disclosure are pharmaceutical composition comprising the immunogenic glycopeptide; and method for preventing and/or treating a cancer.
NEW Cmv vectors comprising microrna recognition elements
May 25, 2017 - N°20170143809

Disclosed herein are recombinant cmv vectors comprising heterologous antigens and microrna recognition elements to silence expression of cmv genes in the presence of microrna derived from myeloid cells, an active ul128 protein and an active ul130 protein. Also disclosed are recombinant cmv vectors comprising heterologous antigens and microrna recognition elements to silence expression of cmv genes in the presence of ...
NEW Use of cinnabarinic acid as a modulator of immune response in autoimmune disorders
May 25, 2017 - N°20170143727

The present invention provides compounds and methods for preventing and treating an immune disorder in a subject.
NEW Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
Merial, Inc.
May 18, 2017 - N°20170137843

The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an ox40l polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the ox40l polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. ...
Therapeutic antibodies
Merial, Inc.
May 18, 2017 - N°20170137529

A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an ...
Gitr antibodies and methods of inducing or enhancing an immune response
Gitr, Inc.
May 18, 2017 - N°20170137527

The present invention provides binding molecules that specifically bind to gitr, e. G., human gitr (hgitr), on t cells and dendritic cells. Binding molecules of the invention are characterized by binding to hgitr with high affinity, in the presence of a stimulating agent, e. G., cd3, are agonistic, and abrogate the suppression of teff cells by treg cells. Various aspects ...
Ctla4 binders
Gitr, Inc.
May 18, 2017 - N°20170137521

The present invention provides molecules, such as isvds and nanobodies, that bind to ctla4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules ...
Pd1/ctla4 binders
Gitr, Inc.
May 18, 2017 - N°20170137520

The present invention provides multispecific molecules, e. G., comprising more than one isvd or nanobody, that bind to pd1 and ctla4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease ...
Pd1 and/or lag3 binders
Gitr, Inc.
May 18, 2017 - N°20170137517

The present invention provides molecules, such as isvds and nanobodies, that bind to pd1 and lag3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious ...
Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
Bristol-myers Squibb Company
May 18, 2017 - N°20170137514

The present invention provides isolated monoclonal antibodies that specifically bind lag-3, and have optimized functional properties compared to previously described anti-lag-3 antibodies, such as antibody 25f7 (us 2011/0150892 a1). These properties include reduced deamidation sites, while still retaining high affinity binding to human lag-3, and physical (i. E., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, ...
Tgf-ß1 specific antibodies and methods and uses thereof
Bristol-myers Squibb Company
May 18, 2017 - N°20170137507

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (tgf-β1) are provided, particularly recognizing human and mouse tgf-β1 and not recognizing or binding tgf-β2 or tgf-β3. Particular antibodies are provided which specifically recognize and neutralize tgf-β1. These antibodies are useful in the diagnosis and ...